2.05

10.09% -0.23

After Hours: 2.05

Carmell Therapeutics Corp (CTCX)

Overview News Price History Discussions Forecast

Carmell Therapeutics Corp stock is currently priced at $2.05, with a 24-hour trading volume of 28,006. It has seen a -10.09% decreased in the last 24 hours and a -6.82% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.28 pivot point. If it approaches the $2.28 support level, significant changes may occur.

Previous Close:

$2.28

Open:

$2.08

24h Volume:

28,006

Market Cap:

$42.50M

Revenue:

Net Income/Loss:

$-11.11M

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+0.00%

1M Performance:

-6.82%

6M Performance:

-7.66%

1Y Performance:

+0.00%

1D Range:

$2.05

$2.34

52W Range:

$1.70

$5.27

Carmell Therapeutics Corp Stock (CTCX) Company Profile

Name

Carmell Therapeutics Corp

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

412 894 8248

Address

2403 Sidney Street, Suite 300, Pittsburgh

Employee

Twitter

Next Earnings Date

Latest SEC Filings

CTCX's Discussions on Twitter

Carmell Therapeutics Corp Stock (CTCX) Latest News

Carmell Therapeutics selling Axolotl Biologix subsidiary - TipRanks.com - TipRanks

TipRanks

Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary

GlobeNewswire Inc.

Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field

GlobeNewswire Inc.

Carmell Therapeutics Corp Stock (CTCX) Financials Data

Carmell Therapeutics Corp (CTCX) Net Income 2024

CTCX net income (TTM) was -$11.11 million for the quarter ending December 31, 2023.

Carmell Therapeutics Corp (CTCX) Earnings per Share 2024

CTCX earnings per share (TTM) was -$2.4155 for the quarter ending December 31, 2023.

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.